Literature DB >> 24781050

Differential effect of vitamin D on NOD2- and TLR-induced cytokines in Crohn's disease.

S Dionne1, M R Calderon2, J H White2, B Memari2, I Elimrani1, B Adelson1, C Piccirillo1, E G Seidman1.   

Abstract

Accumulating evidence implicates defective innate immunity in the pathogenesis of Crohn's disease (CD). Ineffectual NOD2 (nucleotide-binding oligomerization domain 2) is the most common susceptibility gene contributing to CD. Vitamin D (vD), a potent modulator of innate and adaptive immunity, induces NOD2 gene expression and its downstream function. We hypothesized that the hormonal form of vD (1,25D) could beneficially modulate innate immune function in CD. Using peripheral mononuclear cells and monocyte-derived dendritic cells (Mo-DCs) from CD, it was found that 1,25D decreased Toll-like receptor (TLR)-induced cytokine production and enhanced cytokine levels induced by muramyl dipeptide (MDP), the NOD2 ligand. 1,25D increased the synergistic effect provided by NOD2 and TLR co-activation on interleukin (IL)-10, IL-23, and tumor necrosis factor-alpha (TNF-α). Whereas 1,25D inhibits Mo-DC TLR-induced cytokines, co-stimulation of NOD2 results in increased IL-10 and IL-23. IL-12p70 was completely abrogated by 1,25D. 1,25D similarly modulated cytokine production by immune cells in ulcerative colitis patients and healthy controls. Mo-DCs from CD patients heterozygous for NOD2 mutations had a response similar to those from patients without NOD2 mutations. Immune cells from patients homozygous for the 1007 fs mutation were unresponsive to MDP and 1,25D. Our in vitro data support 1,25D as a potential modulator of immunity. However, these results cannot be extrapolated to CD patients without further controlled studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24781050     DOI: 10.1038/mi.2014.30

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  50 in total

Review 1.  Genetic predisposition to autoimmunity--what have we learned?

Authors:  Ekta Rai; Edward K Wakeland
Journal:  Semin Immunol       Date:  2011-02-01       Impact factor: 11.130

Review 2.  The geoepidemiology of autoimmune intestinal diseases.

Authors:  Ian Logan; Christopher L Bowlus
Journal:  Autoimmun Rev       Date:  2009-11-10       Impact factor: 9.754

Review 3.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

4.  Geographical variation and incidence of inflammatory bowel disease among US women.

Authors:  Hamed Khalili; Edward S Huang; Ashwin N Ananthakrishnan; Leslie Higuchi; James M Richter; Charles S Fuchs; Andrew T Chan
Journal:  Gut       Date:  2012-01-11       Impact factor: 23.059

5.  Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease.

Authors:  D A van Heel; S Ghosh; K A Hunt; C G Mathew; A Forbes; D P Jewell; R J Playford
Journal:  Gut       Date:  2005-05-31       Impact factor: 23.059

6.  Mechanism of 1α,25-dihydroxyvitamin D(3)-dependent repression of interleukin-12B.

Authors:  Petra Gynther; Sari Toropainen; Juha M Matilainen; Sabine Seuter; Carsten Carlberg; Sami Väisänen
Journal:  Biochim Biophys Acta       Date:  2011-02-18

Review 7.  Review article: vitamin D and inflammatory bowel disease--established concepts and future directions.

Authors:  M Garg; J S Lubel; M P Sparrow; S G Holt; P R Gibson
Journal:  Aliment Pharmacol Ther       Date:  2012-06-12       Impact factor: 8.171

8.  Interaction among vitamin D(3) analogue KH 1060, TNF-alpha, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients.

Authors:  Maria Stio; Maria Martinesi; Sara Bruni; Cristina Treves; Giuseppe d'Albasio; Siro Bagnoli; Andrea G Bonanomi
Journal:  Int Immunopharmacol       Date:  2006-02-23       Impact factor: 4.932

9.  NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes.

Authors:  Vanessa Beynon; Sebastian Cotofana; Stephan Brand; Peter Lohse; Anja Mair; Stefanie Wagner; Thomas Mussack; Thomas Ochsenkühn; Matthias Folwaczny; Christian Folwaczny; Jürgen Glas; Helga-Paula Török
Journal:  Inflamm Bowel Dis       Date:  2008-08       Impact factor: 5.325

10.  Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

Authors:  S P Jørgensen; J Agnholt; H Glerup; S Lyhne; G E Villadsen; C L Hvas; L E Bartels; J Kelsen; L A Christensen; J F Dahlerup
Journal:  Aliment Pharmacol Ther       Date:  2010-05-11       Impact factor: 8.171

View more
  9 in total

Review 1.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

2.  Vitamin D signaling maintains intestinal innate immunity and gut microbiota: potential intervention for metabolic syndrome and NAFLD.

Authors:  Yilan Zeng; Mei Luo; Liwei Pan; Yuan Chen; Siqi Guo; Dongxia Luo; Li Zhu; Yong Liu; Lisha Pan; Siya Xu; Ruofei Zhang; Chunyan Zhang; Pengfei Wu; Liangpeng Ge; Mazen Noureddin; Stephen J Pandol; Yuan-Ping Han
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-27       Impact factor: 4.052

3.  High-dose vitamin D3 supplementation decreases the number of colonic CD103+ dendritic cells in healthy subjects.

Authors:  Nina Friis Bak; M Bendix; S Hald; L Reinert; M K Magnusson; J Agnholt
Journal:  Eur J Nutr       Date:  2017-09-14       Impact factor: 5.614

4.  Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases.

Authors:  R W Winter; E Collins; B Cao; M Carrellas; A M Crowell; J R Korzenik
Journal:  Aliment Pharmacol Ther       Date:  2017-01-10       Impact factor: 8.171

5.  The differential effects of 1,25-dihydroxyvitamin D3 on Salmonella-induced interleukin-8 and human beta-defensin-2 in intestinal epithelial cells.

Authors:  F-C Huang
Journal:  Clin Exp Immunol       Date:  2016-04-12       Impact factor: 4.330

6.  1,25-hydroxyvitamin D relieves colitis in rats via down-regulation of toll-like receptor 9 expression.

Authors:  Zhang-Han Dai; Bei Tan; Hong Yang; Ou Wang; Jia-Ming Qian; Hong Lv
Journal:  Croat Med J       Date:  2015-12       Impact factor: 1.351

7.  NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn's disease patients.

Authors:  Holger Schäffler; Maria Rohde; Sarah Rohde; Astrid Huth; Nicole Gittel; Hannes Hollborn; Dirk Koczan; Änne Glass; Georg Lamprecht; Robert Jaster
Journal:  World J Gastroenterol       Date:  2018-03-21       Impact factor: 5.742

8.  MetaboAnalystR 3.0: Toward an Optimized Workflow for Global Metabolomics.

Authors:  Zhiqiang Pang; Jasmine Chong; Shuzhao Li; Jianguo Xia
Journal:  Metabolites       Date:  2020-05-07

9.  A New Model Based on 25-Hydroxyvitamin D3 for Predicting Active Crohn's Disease in Chinese Patients.

Authors:  Sinan Lin; Ying Wang; Li Li; Peng Chen; Ren Mao; Rui Feng; Yun Qiu; Yao He; Baili Chen; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Mediators Inflamm       Date:  2018-12-16       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.